Published in J Thorac Oncol on November 01, 2011
Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol (2012) 1.59
Malignant pleural mesothelioma: current and future perspectives. J Thorac Dis (2013) 0.91
Hyaluronan and N-ERC/mesothelin as key biomarkers in a specific two-step model to predict pleural malignant mesothelioma. PLoS One (2013) 0.90
Comparison of the diagnostic accuracy of the MSLN gene products, mesothelin and megakaryocyte potentiating factor, as biomarkers for mesothelioma in pleural effusions and serum. Dis Markers (2013) 0.88
Diagnostic and prognostic value of soluble syndecan-1 in pleural malignancies. Biomed Res Int (2014) 0.80
Radical surgery for malignant pleural mesothelioma: have we identified the appropriate selection tools? Ann Cardiothorac Surg (2012) 0.76
The continual search for ideal biomarkers for mesothelioma: the hurdles. J Thorac Dis (2013) 0.76
A Novel Panel of Serum Biomarkers for MPM Diagnosis. Dis Markers (2017) 0.75
Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma. Oncotarget (2017) 0.75
Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin. BMC Cancer (2017) 0.75
Clinical significance of serum CA125 in diffuse malignant mesothelioma. Springerplus (2016) 0.75
Prognostication and monitoring of mesothelioma using biomarkers: a systematic review. Br J Cancer (2017) 0.75
Diagnosis and prognosis-review of biomarkers for mesothelioma. Ann Transl Med (2017) 0.75
Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moonshot? Oncotarget (2017) 0.75
Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysis. Oncotarget (2017) 0.75
High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med (2005) 7.20
Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat Genet (2009) 6.91
Management of lung nodules detected by volume CT scanning. N Engl J Med (2009) 6.79
Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nat Genet (2008) 6.69
Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst (2007) 4.40
Mediastinoscopy vs endosonography for mediastinal nodal staging of lung cancer: a randomized trial. JAMA (2010) 4.08
Characteristics of lung cancers detected by computer tomography screening in the randomized NELSON trial. Am J Respir Crit Care Med (2013) 3.47
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol (2010) 3.30
Testing for recombinant human erythropoietin. J Appl Physiol (1985) (2008) 3.02
Biological and clinical aspects of the vitamin D binding protein (Gc-globulin) and its polymorphism. Clin Chim Acta (2006) 2.97
Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON). Int J Cancer (2007) 2.85
Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat Genet (2009) 2.76
Initial analysis of the international association for the study of lung cancer mesothelioma database. J Thorac Oncol (2012) 2.57
A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. Nat Genet (2010) 2.56
Proteomic analysis of exosomes isolated from human malignant pleural effusions. Am J Respir Cell Mol Biol (2004) 2.44
Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin Cancer Res (2003) 2.28
Endoscopic ultrasound reduces surgical mediastinal staging in lung cancer: a randomized trial. Am J Respir Crit Care Med (2007) 2.26
Positron emission tomography in mantle cell lymphoma. Leuk Lymphoma (2008) 2.12
False-positive detection of recombinant human erythropoietin in urine following strenuous physical exercise. Blood (2006) 2.06
Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study. J Clin Oncol (2009) 1.90
Nodule management protocol of the NELSON randomised lung cancer screening trial. Lung Cancer (2006) 1.89
The association between smoking, beverage consumption, diet and bladder cancer: a systematic literature review. World J Urol (2003) 1.72
Assessment of renal function in recently admitted critically ill patients with normal serum creatinine. Nephrol Dial Transplant (2005) 1.72
EBUS-TBNA for the diagnosis of central parenchymal lung lesions not visible at routine bronchoscopy. Lung Cancer (2008) 1.69
Serum cystatin C concentration compared with other markers of glomerular filtration rate in the old old. J Am Geriatr Soc (2002) 1.68
EBUS-TBNA for the clarification of PET positive intra-thoracic lymph nodes-an international multi-centre experience. J Thorac Oncol (2009) 1.60
Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol (2012) 1.59
European genome-wide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene. Hum Mol Genet (2011) 1.58
Hypersensitivity pneumonitis due to molds in a saxophone player. Chest (2010) 1.58
Additional value of whole-body fluorodeoxyglucose positron emission tomography in the detection of distant metastases of non-small-cell lung cancer. Clin Lung Cancer (2003) 1.50
Development of an affordable dye-stained microalbuminuria screening test. Nephrol Dial Transplant (2008) 1.50
A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03). Eur J Cancer (2011) 1.48
Expressed wishes and incidence of euthanasia in advanced lung cancer patients. Eur Respir J (2012) 1.46
Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). Eur J Cancer (2006) 1.43
Volumetric computed tomography screening for lung cancer: three rounds of the NELSON trial. Eur Respir J (2013) 1.42
Faecal leukocyte esterase activity is an alternative biomarker in inflammatory bowel disease. Clin Chem Lab Med (2015) 1.41
Mediastinal emphysema and small cell lung cancer (SCLC): a case-report. Lung Cancer (2005) 1.38
Lung function in idiopathic pulmonary fibrosis--extended analyses of the IFIGENIA trial. Respir Res (2009) 1.34
Neutrophil:lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung, and kidney cancer surgery. Ann Surg Oncol (2013) 1.32
Projected future climate change and Baltic Sea ecosystem management. Ambio (2015) 1.32
Are men with low selenium levels at increased risk of prostate cancer? Eur J Cancer (2006) 1.31
Epidemiology of chronic non-cancer pain in Europe: narrative review of prevalence, pain treatments and pain impact. Curr Med Res Opin (2011) 1.29
The crazy-paving pattern: a radiological-pathological correlation. Insights Imaging (2011) 1.29
Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma. Lung Cancer (2004) 1.28
Validation of computational fluid dynamics in CT-based airway models with SPECT/CT. Radiology (2010) 1.27
Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: new aspects and applications. Clin Chim Acta (2008) 1.23
The role of conventional bronchoscopy in the workup of suspicious CT scan screen-detected pulmonary nodules. Chest (2012) 1.23
A meta-analysis on the association between bladder cancer and occupation. Scand J Urol Nephrol Suppl (2008) 1.20
A statistical approach to central monitoring of data quality in clinical trials. Clin Trials (2012) 1.17
The relevance of marine chemical ecology to plankton and ecosystem function: an emerging field. Mar Drugs (2011) 1.16
Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials. Support Care Cancer (2010) 1.15
Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma. Am J Respir Crit Care Med (2010) 1.14
Additional value of PET-CT in staging of clinical stage IIB and III breast cancer. Breast J (2010) 1.13
A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer. Lung Cancer (2009) 1.11
Increased IL-6 and TGF-beta1 concentrations in bronchoalveolar lavage fluid associated with thoracic radiotherapy. Int J Radiat Oncol Biol Phys (2004) 1.11
A meta-analysis on depression and subsequent cancer risk. Clin Pract Epidemiol Ment Health (2007) 1.10
Diagnostic value of the hemopexin N-glycan profile in hepatocellular carcinoma patients. Clin Chem (2010) 1.09
Prohepcidin accumulates in renal insufficiency. Clin Chem Lab Med (2004) 1.09
Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol (2008) 1.09
Alpha 1-microglobulin: clinical laboratory aspects and applications. Clin Chim Acta (2004) 1.08
Do intraoperative analgesics influence breast cancer recurrence after mastectomy? A retrospective analysis. Anesth Analg (2010) 1.07
Temporary cyst formation in phytoplankton: a response to allelopathic competitors? Environ Microbiol (2004) 1.07
Progression-free survival rate as primary end point for phase II cancer clinical trials: application to mesothelioma--The EORTC Lung Cancer Group. J Clin Oncol (2006) 1.07
'Black Spots' and hyaline pleural plaques on the parietal pleura of 150 urban necropsy cases. Am J Surg Pathol (2002) 1.07
Survival determinants in lung transplant patients with chronic allograft dysfunction. Transplantation (2011) 1.05
Tumor necrosis factor receptors: biology and therapeutic potential in kidney diseases. Am J Nephrol (2012) 1.05
Analytical interferences in point-of-care testing glucometers by icodextrin and its metabolites: an overview. Perit Dial Int (2009) 1.05
Increased urinary neutrophil gelatinase associated lipocalin in urinary tract infections and leukocyturia. Clin Chem Lab Med (2011) 1.05
Change in the actin cytoskeleton during seismonastic movement of Mimosa pudica. Plant Cell Physiol (2006) 1.04
[High-throughput screening method of KRAS mutations at codons 12 and 13 in formalin-fixed paraffin-embedded tissue specimens of metastatic colorectal cancer]. Gan To Kagaku Ryoho (2011) 1.03
SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition. Clin Cancer Res (2003) 1.02
Intensity-modulated radiotherapy for locally advanced non-small-cell lung cancer: a dose-escalation planning study. Int J Radiat Oncol Biol Phys (2010) 1.01
Epidemiology of chronic pain in denmark and sweden. Pain Res Treat (2012) 1.01
Can elective nodal irradiation be omitted in stage III non-small-cell lung cancer? Analysis of recurrences in a phase II study of induction chemotherapy and involved-field radiotherapy. Int J Radiat Oncol Biol Phys (2002) 1.00
Surgery in mesothelioma--where do we go after MARS? J Thorac Oncol (2013) 1.00
ChemR23 dampens lung inflammation and enhances anti-viral immunity in a mouse model of acute viral pneumonia. PLoS Pathog (2011) 0.99
Hypofractionated external beam radiotherapy as retreatment for symptomatic non-small-cell lung carcinoma: an effective treatment? Int J Radiat Oncol Biol Phys (2004) 0.99
European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer. Clin Cancer Res (2003) 0.99
Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels. Thromb Haemost (2014) 0.98